Atlas Trials

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Clinical trial NCT01822652 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT01822652
Sponsor
Baylor College of Medicine
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neuroblastoma
Start date
2013-08-01
Primary completion
2015-12-01
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.